Individuals using Wegovy report lower levels of food-related distractions and enhanced mental health benefits
In a groundbreaking development, Novo Nordisk has announced the results of a US-based survey on the impact of their weight management drug, Wegovy, on individuals living with overweight or obesity. The findings were presented at the European Association for the Study of Diabetes (EASD) 2025 in Vienna, Austria.
According to the survey, a substantial majority (76% and 80%) of individuals reported developing a healthier lifestyle and healthier habits since starting Wegovy treatment, respectively. Moreover, around 8 in 10 (83%) of individuals in the study were satisfied with their Wegovy treatment.
One of the most significant findings was the reduction in food noise, which refers to unwanted and intrusive thoughts about food that can affect mental well-being, quality of life, and weight loss efforts. The decline in the number of people experiencing constant thoughts about food throughout the day was 46%, as reported by 62% before starting Wegovy versus 16% on Wegovy.
Filip Knop, senior vice president and head of Medical & Translational Science at Novo Nordisk, stated that the new data suggests Wegovy may help quiet disruptive thoughts about food and support improved mental wellbeing. He further added that Wegovy may enable people to live healthier lives.
The proportion of participants who reported that food noise had a negative effect on their lives dropped from 60% before starting treatment to 20% for respondents on Wegovy treatment. This indicates a significant improvement in the mental well-being of those taking Wegovy.
Around two-thirds (64%) of respondents reported that their mental health improved since starting Wegovy treatment. The findings from the survey add to the growing evidence of the broad health benefits of semaglutide in people with obesity, alongside its established effect on weight loss.
An upcoming presentation at EASD will highlight eating behavior and control of eating with semaglutide from the STEP UP clinical trial findings. Dr. John P. H. Wilding, the author of the study on the effect of Wegovy in reducing food noise in people working on weight management, will present these findings.
Novo Nordisk continues to investigate how obesity impacts individuals' day-to-day lives, and the results from the INFORM survey and the STEP UP clinical trial are a significant step forward in understanding the potential benefits of Wegovy in improving the lives of those living with overweight or obesity.
Read also:
- Hospital's Enhancement of Outpatient Services Alleviates Emergency Department Strain
- Increased Chikungunya infections in UK travelers prompt mosquito bite caution
- Kazakhstan's Deputy Prime Minister holds discussions on the prevailing circumstances in Almaty
- In the state, Kaiser Permanente boasts the top-ranked health insurance program
